ClinicalTrials.gg
CompletedNCT01698918BOLERO-4Updated May 3, 2023Results posted

Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer

A Phase 2 interventional study of Everolimus and Letrozole in Hormone Receptor Positive Breast Cancer, sponsored by Novartis Pharmaceuticals. Completed at 52 sites in 13 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-05-03.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
202
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 78 studies testing everolimus in Breast Neoplasms — 7 open to participants now, 10 under way, 6 of them phase 3. Everolimus · Breast Neoplasms.

Enrollment
19th of 78
202 · median 55
Started
2013
with 10 others
Phase 2
40 of 78
3 open now
Registered
37th of 78
by date
Lead sponsor
14 of 78
Novartis Pharmaceuticals

Among the 78 studies testing everolimus in Breast Neoplasms, this one is the 19th largest by enrollment, is one of 11 that started in 2013, is one of 40 in phase 2, and was the 37th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

7 of the 78 studies testing everolimus in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About everolimus

Everolimus: first FDA approval 2009 (AFINITOR), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 78 studies testing everolimus in Breast Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study was to assess the efficacy and safety of first-line treatment with everolimus plus letrozole in postmenopausal women with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) locally advanced or metastatic breast cancer.

Moreover, the study also aimed to investigate the efficacy and safety of second line treatment with everolumus plus examestane in participants whose disease progressed during everolimus plus letrozole therapy.

Read the detailed description

This was an open-label, phase II, multicenter, international, single-arm study for postmenopausal women with ER+/HER2- metastatic or locally advanced breast cancer.

This study was comprised of 2 phases:

  • Core Phase: from first participant first visit to 24 months after enrollment of the last participant (and upon approval of amendment 5 dated 14-Feb-2017), up to approximately 4 years. The main purpose of the amendment 5 was to implement an Extension Phase up to 3 years.

During the core phase, all enrolled participants received everolimus in combination with letrozole in the first line setting until disease progression or any other reason for which the participant might be discontinued. Only those participants who had disease progression in the first line setting were offered second line treatment (everolimus in combination with exemestane). Participants who discontinued first line treatment due to reasons other than disease progression were not eligible for second line treatment. The participants who were treated in the second line setting continued treatment until disease progression, unacceptable toxicity or withdrawal of consent.

  • Extension Phase: Participants that were still benefiting from everolimus at the end of the Core Phase (and upon approval of amendment 5 dated 14-Feb-2017) were transitioned to the Extension phase of the study. Participants were continued on their existing line of treatment (everolimus plus letrozole or everolimus plus exemestane) in the extension, up to 3 years or until progression or any other reason for which the participant might be discontinued. Participants entering the Extension Phase on first line treatment and deemed to no longer be clinically benefiting were not offered second line treatment in the context of the study

This study included a randomized, open-label sub-study for participants in countries where the alcohol-free 0.5mg/5ml dexamethasone oral solution was commercially available who experienced a stomatitis event: at the first onset of symptoms suggestive of stomatitis, participants were to contact the study site and based on preliminary confirmation of diagnosis, participants were asked to visit the study site within 24 hours. Upon confirmation of stomatitis, participants in countries where the alcohol-free 0.5 mg/5 mL dexamethasone oral solution was commercially available (US sites only) were randomly assigned in a 1:1 ratio to take either 0.5 mg/5 mL dexamethasone mouth rinse or the standard of care used to treat stomatitis at the participant's center.

All participants who experienced stomatitis (regardless of inclusion in the sub-study) were instructed to fill out the Oral Stomatitis Daily Questionnaire (OSDQ) at home every day until the participant recovered. For subsequent episodes of stomatitis, participants were instructed to contact the physician. If part of the randomized set upon telephone confirmation, they were instructed to utilize the same treatment they were assigned to after the first episode and complete the OSDQ booklet.

03

Conditions studied

  • Hormone Receptor Positive Breast Cancer

Browse trials for

Keywords

  • Metastatic breast cancer
  • Locally advanced breast cancer
  • HER2-
  • ER+
  • Everolimus
  • Afinitor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with or locally advanced, unresectable breast cancer not amenable to curative treatment by surgery or radiotherapy
  • Histological or cytological confirmation of ER+/ - breast cancer
  • women
  • No prior treatment for metastatic breast cancer

Exclusion criteria

Exclusion Criteria:

  • Patients with only non- other than bone (e.g., pleural effusion, ascites, etc)
  • Patients who had received prior hormonal or any other systemic therapy for metastatic breast cancer. Patients might have received prior or adjuvant endocrine therapy. In the case of neoadjuvant or adjuvant NSAI (letrozole/anastrozole) therapy patients must have completed therapy at least 1 year prior to study enrollment.
  • Previous treatment with mTOR inhibitors.
  • Known to mTOR inhibitors, e.g., sirolimus (rapamycin).

Other protocol-defined inclusion/exclusion criteria might apply

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
202 participants (actual)

Study arms

  • Experimental
    Everolimus+letrozole/exemestane (first line and second line treatment)

    Participants received everolimus in combination with letrozole as first-line treatment. Only participants who had disease progression in the first line setting (core phase) were offered second-line treatment (everolimus in combination with exemestane)

    Drug: Everolimus · Drug: Letrozole · Drug: Exemestane · Drug: Alcohol-free dexamethasone mouth rinse (Stomatitis sub-study) · Drug: Standard of care to treat stomatitis (Stomatitis sub-study)

Interventions

  • Everolimus was self-administered as a daily dose of 10mg (two 5mg tablets) taken orally continuously until progression of disease, unacceptable toxicity or withdrawal of consent.

    Also known as: RAD001

  • 1st line study treatment: Letrozole was self administered as a daily dose of 2.5mg continuously until disease progression or any other reason for which the patient might be discontinued

    Also known as: Femara

  • 2nd Line Study Treatment: Exemestane was self administered as a daily dose of 25mg taken orally continuously until disease progression or any other reason for which the patient might be discontinued

    Also known as: Aromasin

  • DrugAlcohol-free dexamethasone mouth rinse (Stomatitis sub-study)

    Alcohol-free 0.5mg/5ml dexamethasone oral solution was self-administered at a daily dose of 10ml 3 times per day (participants with confirmed stomatitis who entered the stomatitis sub-study).

  • DrugStandard of care to treat stomatitis (Stomatitis sub-study)

    Standard of care used to treat stomatitis at the patient's center (participants with confirmed stomatitis who entered the stomatitis sub-study).

06

What researchers measure

Primary outcomes

  1. First-line Treatment: Progression-free Survival (PFS)

    PFS in the first line setting is defined as the time from the date of enrollment to the date of first documented progression based on local radiology review or death due to any cause. If a participant did not progress or was not known to have died at the date of the analysis cut-off or start of another antineoplastic therapy, the PFS date was censored to the date of last adequate tumor assessment prior to cut-off date or start of antineoplastic therapy. The median PFS was estimated and presented along with 95% confidence intervals. The primary analysis of PFS for first line was performed 12 months after the last patient's recruitment.

    Time frame: From the date of enrollment to the date of first documented progression or deaths, assessed up to approximately 2.8 years

Secondary outcomes

  1. First-line Treatment: Overall Response Rate (ORR)

    ORR in first line setting is defined as the percentage of participants while on first-line treatment with best overall response of complete response (CR) or partial response (PR) according to RECIST version 1.0 based on local review. Confidence intervals were calculated based on the Exact Clopper-Pearson method. ORR while on first-line treatment was assessed up to 24 months after the last patient's recruitment. CR: disappearance of all target lesions PR: at least a 30% decrease in the sum of the longest diameter of all target lesions, taking as reference the baseline sum of the longest diameters.

    Time frame: From the date of enrollment until discontinuation of first-line treatment, assessed up to approximately 3.8 years

  2. First-line Treatment: Clinical Benefit Rate (CBR)

    CBR in first line is defined as the percentage of participants while on first-line treatment with best overall response of CR, PR or stable disease (SD) with a duration of 24 weeks or longer, according to RECIST version 1.0 based on local review. Confidence intervals (CI) were calculated based on the Exact Clopper-Pearson method. CBR while on first-line treatment was assessed up to 24 months after the last patient's recruitment. CR: disappearance of all target lesions PR: at least a 30% decrease in the sum of the longest diameter of all target lesions, taking as reference the baseline sum of the longest diameters. SD: Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for progressive disease

    Time frame: From the date of enrollment until first-line treatment discontinuation, assessed up to approximately 3.8 years

  3. Second-line Treatment: Progression-free Survival (PFS)

    PFS in the second line setting is defined as the time interval between the start of the second-line treatment and documented disease progression based on local radiology review or death due to any cause reported during or after second-line treatment period. If a participant did not progress or was not known to have died at the date of the analysis cut-off or start of another antineoplastic therapy, the PFS date was censored to the date of last adequate tumor assessment prior to cut-off date or start of antineoplastic therapy. The median PFS was estimated and presented along with 95% confidence intervals. PFS while on second-line treatment was assessed up to 24 months after the last patient's recruitment.

    Time frame: From the start of the second-line treatment until the date of first documented progression or death, assessed up to approximately 2.4 years

  4. Second-line Treatment: Overall Response Rate (ORR)

    ORR in second line is defined as the percentage of participants receiving second-line study treatment with best overall response of complete response (CR) or partial response (PR) according to RECIST version 1.0 based on local review. Confidence intervals (CI) were calculated based on the Exact Clopper-Pearson method. ORR while on second-line treatment was assessed up to 24 months after the last patient's recruitment. CR: disappearance of all target lesions PR: at least a 30% decrease in the sum of the longest diameter of all target lesions, taking as reference the baseline sum of the longest diameters

    Time frame: From the start of the second-line treatment up to approximately 2.4 years

  5. Second-line Treatment: Clinical Benefit Rate (CBR)

    CBR in second line is defined as the percentage of participants receiving second-line study treatment with best overall response of CR, PR or stable disease (SD) with a duration of 24 weeks or longer, according to RECIST version 1.0 based on local review. Confidence intervals (CI) were calculated based on the Exact Clopper-Pearson method. CBR while on second-line treatment was assessed up to 24 months after the last patient's recruitment. CR: disappearance of all target lesions PR: at least a 30% decrease in the sum of the longest diameter of all target lesions, taking as reference the baseline sum of the longest diameters. SD: Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for progressive disease

    Time frame: From the start of the second-line treatment up to approximately 2.4 years

  6. Overall Survival (OS)

    OS following first-line treatment with everolimus + letrozole is defined as the time from the date of receiving first line study treatment to date of death due to any cause (including first-line and second-line treatment periods). If a participant was not known to have died, survival was censored at the date of last contact. OS following first-line treatment was assessed up to 24 months after last patient's recruitment.

    Time frame: From the date of enrollment to date of death, assessed up to approximately 3.8 years

  7. First-line Treatment: Time to First Stomatitis Episode as Assessed by the Oral Stomatitis Daily Questionnaire (OSDQ)

    The time to first occurrence of stomatitis based on OSDQ is defined as time from first-line treatment administration to start date of the stomatitis episode recorded in the OSDQ in the first line. The OSDQ is a patient self-administered 6-item questionnaire with a 24-hour recall period. Participants completed the questionnaire daily until the resolution of the stomatitis episode. The first item asked the participants when they experienced the first symptoms of stomatitis. Start date of the first occurrence of stomatitis is defined as the first date ever recorded for this item in the questionnaire. Patient reported outcomes (PROs) were assessed up to 24 months after last patient's recruitment.

    Time frame: From first-line treatment administration until first stomatitis episode in the first line, assessed up to approximately 3.8 years

  8. First-line Treatment: Duration of First Stomatitis Based on OSDQ

    The duration of the first stomatitis episode was calculated using the start and end date recorded in the OSDQ. The OSDQ is a patient self-administered 6-item questionnaire with a 24-hour recall period. Participants completed the questionnaire daily until the resolution of the stomatitis. The first item of the questionnaire asked the participants the date when they experienced the first symptoms of stomatitis. Start date of the first occurrence of stomatitis is defined as the first date ever recorded for this item in the questionnaire. Stop date of the first stomatitis episode is defined as the last date the OSDQ was completed for this episode. Participants were censored if they died before resolution of stomatitis, received a new anticancer therapy, discontinued the study treatment with no resolution of the stomatitis or the stomatitis event was still on-going at the cut-off. PROs were assessed up to 24 months after last patient's recruitment.

    Time frame: From start date of first stomatitis episode in first line until its resolution, assessed up to 3.8 years

  9. First-line Treatment: Number of Participants With Shift of Response in OSDQ Score on Overall Health at the End of the First Stomatitis Episode

    The OSDQ is a patient self-administered 6-item questionnaire with a 24-hour recall period. Participants completed the questionnaire daily up to the resolution of the stomatitis episode. The second item asked the participant to rate their overall health from 0 (worst possible) to 10 (perfect health). The overall health OSDQ scores are presented as the shift from Day 1 of first stomatitis episode value to the value at the end of the first episode of stomatitis. Day 1 is defined as the first OSDQ questionnaire recorded. End of first stomatitis value is defined as the last OSDQ questionnaire of the first episode of stomatitis. PROs were assessed up to 24 months after last patient's recruitment.

    Time frame: From start date of first stomatitis episode until its resolution, assessed up to 3.8 years

  10. First-line Treatment: Number of Participants With Shift of Response in OSDQ Score on Mouth and Throat Soreness at the End of the First Stomatitis Episode

    The OSDQ is a patient self-administered 6-item questionnaire with a 24-hour recall period. Participants completed the questionnaire daily until the resolution of the stomatitis episode. The third item asked the participant to rate their mouth and throat soreness from 0 (no soreness) to 4 (extreme soreness). The mouth and throat soreness OSDQ scores are presented as the shift from Day 1 of first stomatitis episode value to the value at the end of the first episode of stomatitis. Day 1 is defined as the first OSDQ questionnaire recorded. End of first stomatitis value is defined as the last OSDQ questionnaire of the first episode of stomatitis. PROs were assessed up to 24 months after last patient's recruitment.

    Time frame: From start date of first stomatitis episode until its resolution, assessed up to 3.8 years

  11. First-line Treatment: Number of Participants With Shift of Response in OSDQ Score on Mouth and Throat Soreness Limiting Swallowing, Drinking, Eating, Talking and Sleeping at the End of the First Stomatitis Episode

    The OSDQ is a patient self-administered 6-item questionnaire with a 24-hour recall period. Participants completed the questionnaire daily until the resolution of the stomatitis episode. The fourth item asked the participant to rate how much their mouth and throat soreness limited them in 1) swallowing, 2) drinking, 3) eating, 4) talking and 5) sleeping. For each activity, mouth and throat soreness scores ranged from 0 (not limited) to 4 (unable to do). Scores are presented as the shift from Day 1 of first stomatitis episode value to the value at the end of the first episode of stomatitis. Day 1 is defined as the first OSDQ questionnaire recorded. End of first stomatitis value is defined as the last OSDQ questionnaire of the first episode of stomatitis. PROs were assessed up to 24 months after last patient's recruitment.

    Time frame: From start date of first stomatitis episode until its resolution, assessed up to 3.8 years

  12. First-line Treatment: Number of Participants With Shift of Response in OSDQ Score on Mouth Pain Severity at the End of the First Stomatitis Episode

    The OSDQ is a patient self-administered 6-item questionnaire with a 24-hour recall period. Participants completed the questionnaire daily until the resolution of the stomatitis episode. The fifth item asked the participant to rate their mouth pain severity from 0 (no pain) to 10 (unbearable pain). The mouth pain severity OSDQ scores are presented as the shift from Day 1 of first stomatitis episode value to the value at the end of the first episode of stomatitis. Day 1 is defined as the first OSDQ questionnaire recorded. End of first stomatitis value is defined as the last OSDQ questionnaire of the first episode of stomatitis. PROs were assessed up to 24 months after last patient's recruitment.

    Time frame: From start date of first stomatitis episode until its resolution, assessed up to 3.8 years

  13. First-line Treatment: Number of Participants With Shift of Response in OSDQ Score on Mouth Pain Severity Affecting Daily Activities at the End of the First Stomatitis Episode

    The OSDQ is a patient self-administered 6-item questionnaire with a 24-hour recall period. Participants completed the questionnaire daily until the resolution of the stomatitis episode. The sixth item asked the participant to rate their mouth pain severity affecting daily activities score from 0 (no effect on daily activities) to 10 (completely prevented from doing daily activities). The mouth pain severity affecting daily activities OSDQ scores are presented as the shift from Day 1 of first stomatitis episode value to the value at the end of the first episode of stomatitis. Day 1 is defined as the first OSDQ questionnaire recorded. End of first stomatitis value is defined as the last OSDQ questionnaire of the first episode of stomatitis. PROs were assessed up to 24 months after last patient's recruitment.

    Time frame: From start date of first stomatitis episode until its resolution, assessed up to 3.8 years

  14. First-line Treatment (Stomatitis Sub-study): Time to First Stomatitis Episode as Assessed by the OSDQ

    The time to first occurrence of stomatitis based on OSDQ is defined as time from first study treatment administration in the first line to start date of the first stomatitis episode recorded in the OSDQ. The OSDQ is a patient self-administered 6-item questionnaire with a 24-hour recall period. Participants completed the questionnaire daily until the resolution of the stomatitis episode. The first item asked the participants when they experienced the first symptoms of stomatitis. Start date of the first occurrence of stomatitis is defined as the first date ever recorded for this item in the questionnaire. PROs were assessed up to 24 months after last patient's recruitment. Only participants who were randomized in the stomatitis sub-study were included in this analysis.

    Time frame: From first study treatment administration in the first line until first stomatitis episode, assessed up to approximately 3.8 years

  15. First-line Treatment (Stomatitis Sub-study): Duration of First Stomatitis Based on OSDQ

    The duration of the first stomatitis was calculated using the start and end date reported in the OSDQ. The OSDQ is a patient self-administered 6-item questionnaire with a 24-hour recall period. Participants completed the questionnaire daily until the resolution of the stomatitis. The first item asked the participants the date when they experienced the first symptoms of stomatitis. Start date of the first stomatitis is defined as the first date ever recorded for this item in the questionnaire. Stop date of the first stomatitis is defined as the last date the OSDQ was completed for this episode. Participants were censored if they died before resolution of stomatitis, received a new anticancer therapy, discontinued the study treatment with no resolution of the stomatitis or the stomatitis was still on-going at the cut-off. PROs were assessed up to 24 months after last patient's recruitment. Only participants who were randomized in the stomatitis sub-study were included in this analysis.

    Time frame: From start date of first stomatitis episode until its resolution, assessed up to 3.8 years

  16. First-line Treatment (Stomatitis Sub-study): Number of Participants With Shift of Response in OSDQ Score on Overall Health at the End of the First Stomatitis Episode

    The OSDQ is a patient self-administered 6-item questionnaire with a 24-hour recall period. Participants completed the questionnaire daily until the resolution of the stomatitis episode. The second item asked the participant to rate their overall health from 0 (worst possible) to 10 (perfect health). The overall health OSDQ score are presented as the shift from Day 1 of first stomatitis episode value to the value at the end of the first episode of stomatitis. Day 1 is defined as the first OSDQ questionnaire recorded. End of first stomatitis value is defined as the last OSDQ questionnaire of the first episode of stomatitis. PROs were assessed up to 24 months after last patient's recruitment. Only participants who were randomized in the stomatitis sub-study were included in this analysis.

    Time frame: From start date of first stomatitis episode until its resolution, assessed up to 3.8 years

  17. First-line Treatment (Stomatitis Sub-study): Number of Participants With Shift of Response in OSDQ Score on Mouth and Throat Soreness at the End of the First Stomatitis Episode

    The OSDQ is a patient self-administered 6-item questionnaire with a 24-hour recall period. Participants completed the questionnaire daily until the resolution of the stomatitis episode. The third item asked the participant to rate their mouth and throat soreness from 0 (no soreness) to 4 (extreme soreness). The mouth and throat soreness OSDQ scores are presented as the shift from Day 1 of first stomatitis episode value to the value at the end of the first episode of stomatitis. Day 1 is defined as the first OSDQ questionnaire recorded. End of first stomatitis value is defined as the last OSDQ questionnaire of the first episode of stomatitis. PROs were assessed up to 24 months after last patient's recruitment. Only participants who were randomized in the stomatitis sub-study were included in this analysis.

    Time frame: From start date of stomatitis episode until its resolution, assessed up to 3.8 years

  18. First-line Treatment (Stomatitis Sub-study): Number of Participants With Shift of Response in OSDQ Score on Mouth and Throat Soreness Limiting Swallowing, Drinking, Eating, Talking and Sleeping at the End of the First Stomatitis Episode

    The OSDQ is a patient self-administered 6-item questionnaire with a 24-hour recall period. Participants completed the questionnaire daily until the resolution of the stomatitis episode. The fourth item asked the participant to rate how much their mouth and throat soreness limited them in 1) swallowing, 2) drinking, 3) eating, 4) talking and 5) sleeping. For each activity, mouth and throat soreness scores ranged from 0 (not limited) to 4 (unable to do). Scores are presented as the shift from Day 1 of first stomatitis stomatitis value to the value at the end of the first episode of stomatitis. Day 1 is defined as the first OSDQ questionnaire recorded. End of first episode value is defined as the last OSDQ questionnaire of the first episode of stomatitis. PROs were assessed up to 24 months after last patient's recruitment. Only participants who were randomized in the stomatitis sub-study were included in this analysis.

    Time frame: From start date of first stomatitis episode until its resolution, assessed up to 3.8 years

  19. First-line Treatment (Stomatitis Sub-study): Number of Participants With Shift of Response in OSDQ Score on Mouth Pain Severity at the End of the First Stomatitis Episode

    The OSDQ is a patient self-administered 6-item questionnaire with a 24-hour recall period. Participants completed the questionnaire daily until the resolution of the stomatitis episode. The fifth item asked the participant to rate their mouth pain severity from 0 (no pain) to 10 (unbearable pain). The mouth pain severity OSDQ scores are presented as the shift from Day 1 of first stomatitis episode value to the value at the end of the first episode of stomatitis. Day 1 is defined as the first OSDQ questionnaire recorded. End of first stomatitis value is defined as the last OSDQ questionnaire of the first episode of stomatitis. PROs were assessed up to 24 months after last patient's recruitment. Only participants who were randomized in the stomatitis sub-study were included in this analysis.

    Time frame: From start date of first stomatitis episode until its resolution, assessed up to 3.8 years

  20. First-line Treatment (Stomatitis Sub-study): Number of Participants With Shift of Response in OSDQ Score on Mouth Pain Severity Affecting Daily Activities at the End of the First Stomatitis Episode

    The OSDQ is a patient self-administered 6-item questionnaire with a 24-hour recall period. Participants completed the questionnaire daily until the resolution of the stomatitis episode. The sixth item asked the participant to rate their mouth pain severity affecting daily activities score from 0 (no effect on daily activities) to 10 (completely prevented from doing daily activities). The mouth pain severity affecting daily activities OSDQ scores are presented as the shift from Day 1 of first stomatitis episode value to the value at the end of the first episode of stomatitis. Day 1 is defined as the first OSDQ questionnaire recorded. End of first stomatitis value is defined as the last OSDQ questionnaire of the first episode of stomatitis. PROs were assessed up to 24 months after last patient's recruitment. Only participants who were randomized in the stomatitis sub-study were included in this analysis.

    Time frame: From start date of first stomatitis episode until its resolution, assessed up to 3.8 years

  21. Number of Participants With Clinical Benfit During Extension Phase

    Number of participants with clinical benefit as judged by the investigator during the extension phase. The extension phase for up to 3 years for participants who were continuing to benefit from study treatment following the end of the core study phase (24 months after last patient's recruitment) was added in the amendment 5 (dated 14-Feb-2017). Results are presented by line of treatment

    Time frame: From the end of core phase (upon approval of amendment 5) up to approximately 3 years

07

Results

Posted Feb 9, 2022

Participant flow

The study was conducted across 52 centers in 13 countries.

First Line Treatment (Core+Extension)
Participant flow — First Line Treatment (Core+Extension)
MilestoneEverolimus+Letrozole/Exemestane (First-line Treatment and Second-line Treatment)
Started202
Dexamethasone randomized set (stomatitis sub-study)11
Standard of care randomized set (stomatitis sub-study)13
Completed29
Not completed173
Withdrew: Adverse event33
Withdrew: Withdrawal by subject11
Withdrew: Death2
Withdrew: Disease progression120
Withdrew: Physician decision7
Second Line Treatment (Core+Extension)
Participant flow — Second Line Treatment (Core+Extension)
MilestoneEverolimus+Letrozole/Exemestane (First-line Treatment and Second-line Treatment)
Started53
Completed7
Not completed46
Withdrew: Adverse event3
Withdrew: Withdrawal by subject1
Withdrew: Death1
Withdrew: Disease progression38
Withdrew: Physician decision3

Outcome measures

PrimaryFirst-line Treatment: Progression-free Survival (PFS)

PFS in the first line setting is defined as the time from the date of enrollment to the date of first documented progression based on local radiology review or death due to any cause. If a participant did not progress or was not known to have died at the date of the analysis cut-off or start of another antineoplastic therapy, the PFS date was censored to the date of last adequate tumor assessment prior to cut-off date or start of antineoplastic therapy. The median PFS was estimated and presented along with 95% confidence intervals. The primary analysis of PFS for first line was performed 12 months after the last patient's recruitment.

Time frame:
From the date of enrollment to the date of first documented progression or deaths, assessed up to approximately 2.8 years
Reported as:
Median · Months
First-line Treatment: Progression-free Survival (PFS)
MonthsEverolimus+Letrozole (First-line Treatment)
First-line Treatment: Progression-free Survival (PFS)NA (18.0 to NA)
SecondaryFirst-line Treatment: Overall Response Rate (ORR)

ORR in first line setting is defined as the percentage of participants while on first-line treatment with best overall response of complete response (CR) or partial response (PR) according to RECIST version 1.0 based on local review. Confidence intervals were calculated based on the Exact Clopper-Pearson method. ORR while on first-line treatment was assessed up to 24 months after the last patient's recruitment. CR: disappearance of all target lesions PR: at least a 30% decrease in the sum of the longest diameter of all target lesions, taking as reference the baseline sum of the longest diameters.

Time frame:
From the date of enrollment until discontinuation of first-line treatment, assessed up to approximately 3.8 years
Reported as:
Number · Percentage of participants
First-line Treatment: Overall Response Rate (ORR)
Percentage of participantsEverolimus+Letrozole (First Line Treatment)
First-line Treatment: Overall Response Rate (ORR)45.0 (38.1 to 52.2)
SecondaryFirst-line Treatment: Clinical Benefit Rate (CBR)

CBR in first line is defined as the percentage of participants while on first-line treatment with best overall response of CR, PR or stable disease (SD) with a duration of 24 weeks or longer, according to RECIST version 1.0 based on local review. Confidence intervals (CI) were calculated based on the Exact Clopper-Pearson method. CBR while on first-line treatment was assessed up to 24 months after the last patient's recruitment. CR: disappearance of all target lesions PR: at least a 30% decrease in the sum of the longest diameter of all target lesions, taking as reference the baseline sum of the longest diameters. SD: Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for progressive disease

Time frame:
From the date of enrollment until first-line treatment discontinuation, assessed up to approximately 3.8 years
Reported as:
Number · Percentage of participants
First-line Treatment: Clinical Benefit Rate (CBR)
Percentage of participantsEverolimus+Letrozole (First-line Treatment)
First-line Treatment: Clinical Benefit Rate (CBR)74.3 (67.7 to 80.1)
SecondarySecond-line Treatment: Progression-free Survival (PFS)

PFS in the second line setting is defined as the time interval between the start of the second-line treatment and documented disease progression based on local radiology review or death due to any cause reported during or after second-line treatment period. If a participant did not progress or was not known to have died at the date of the analysis cut-off or start of another antineoplastic therapy, the PFS date was censored to the date of last adequate tumor assessment prior to cut-off date or start of antineoplastic therapy. The median PFS was estimated and presented along with 95% confidence intervals. PFS while on second-line treatment was assessed up to 24 months after the last patient's recruitment.

Time frame:
From the start of the second-line treatment until the date of first documented progression or death, assessed up to approximately 2.4 years
Reported as:
Median · Months
Second-line Treatment: Progression-free Survival (PFS)
MonthsEverolimus+Exemestane (Second Line Treatment)
Second-line Treatment: Progression-free Survival (PFS)3.7 (1.9 to 7.4)
SecondarySecond-line Treatment: Overall Response Rate (ORR)

ORR in second line is defined as the percentage of participants receiving second-line study treatment with best overall response of complete response (CR) or partial response (PR) according to RECIST version 1.0 based on local review. Confidence intervals (CI) were calculated based on the Exact Clopper-Pearson method. ORR while on second-line treatment was assessed up to 24 months after the last patient's recruitment. CR: disappearance of all target lesions PR: at least a 30% decrease in the sum of the longest diameter of all target lesions, taking as reference the baseline sum of the longest diameters

Time frame:
From the start of the second-line treatment up to approximately 2.4 years
Reported as:
Number · Percentage of participants
Second-line Treatment: Overall Response Rate (ORR)
Percentage of participantsEverolimus+Exemestane (Second-line Treatment)
Second-line Treatment: Overall Response Rate (ORR)6.0 (1.3 to 16.5)
SecondarySecond-line Treatment: Clinical Benefit Rate (CBR)

CBR in second line is defined as the percentage of participants receiving second-line study treatment with best overall response of CR, PR or stable disease (SD) with a duration of 24 weeks or longer, according to RECIST version 1.0 based on local review. Confidence intervals (CI) were calculated based on the Exact Clopper-Pearson method. CBR while on second-line treatment was assessed up to 24 months after the last patient's recruitment. CR: disappearance of all target lesions PR: at least a 30% decrease in the sum of the longest diameter of all target lesions, taking as reference the baseline sum of the longest diameters. SD: Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for progressive disease

Time frame:
From the start of the second-line treatment up to approximately 2.4 years
Reported as:
Number · Percentage of participants
Second-line Treatment: Clinical Benefit Rate (CBR)
Percentage of participantsEverolimus+Exemestane (Second-line Treatment)
Second-line Treatment: Clinical Benefit Rate (CBR)28.0 (16.2 to 42.5)
SecondaryOverall Survival (OS)

OS following first-line treatment with everolimus + letrozole is defined as the time from the date of receiving first line study treatment to date of death due to any cause (including first-line and second-line treatment periods). If a participant was not known to have died, survival was censored at the date of last contact. OS following first-line treatment was assessed up to 24 months after last patient's recruitment.

Time frame:
From the date of enrollment to date of death, assessed up to approximately 3.8 years
Reported as:
Median · Months
Overall Survival (OS)
MonthsEverolimus+Letrozole/Exemestane (First-line Treatment and Second-line Treatment)
Overall Survival (OS)NA (37.0 to NA)
SecondaryFirst-line Treatment: Time to First Stomatitis Episode as Assessed by the Oral Stomatitis Daily Questionnaire (OSDQ)

The time to first occurrence of stomatitis based on OSDQ is defined as time from first-line treatment administration to start date of the stomatitis episode recorded in the OSDQ in the first line. The OSDQ is a patient self-administered 6-item questionnaire with a 24-hour recall period. Participants completed the questionnaire daily until the resolution of the stomatitis episode. The first item asked the participants when they experienced the first symptoms of stomatitis. Start date of the first occurrence of stomatitis is defined as the first date ever recorded for this item in the questionnaire. Patient reported outcomes (PROs) were assessed up to 24 months after last patient's recruitment.

Time frame:
From first-line treatment administration until first stomatitis episode in the first line, assessed up to approximately 3.8 years
Reported as:
Median · Weeks
First-line Treatment: Time to First Stomatitis Episode as Assessed by the Oral Stomatitis Daily Questionnaire (OSDQ)
WeeksEverolimus+Letrozole (First-line Treatment)
First-line Treatment: Time to First Stomatitis Episode as Assessed by the Oral Stomatitis Daily Questionnaire (OSDQ)1.7 (1.3 to 2.1)
SecondaryFirst-line Treatment: Duration of First Stomatitis Based on OSDQ

The duration of the first stomatitis episode was calculated using the start and end date recorded in the OSDQ. The OSDQ is a patient self-administered 6-item questionnaire with a 24-hour recall period. Participants completed the questionnaire daily until the resolution of the stomatitis. The first item of the questionnaire asked the participants the date when they experienced the first symptoms of stomatitis. Start date of the first occurrence of stomatitis is defined as the first date ever recorded for this item in the questionnaire. Stop date of the first stomatitis episode is defined as the last date the OSDQ was completed for this episode. Participants were censored if they died before resolution of stomatitis, received a new anticancer therapy, discontinued the study treatment with no resolution of the stomatitis or the stomatitis event was still on-going at the cut-off. PROs were assessed up to 24 months after last patient's recruitment.

Time frame:
From start date of first stomatitis episode in first line until its resolution, assessed up to 3.8 years
Reported as:
Median · Weeks
First-line Treatment: Duration of First Stomatitis Based on OSDQ
WeeksEverolimus+Letrozole (First-line Treatment)
First-line Treatment: Duration of First Stomatitis Based on OSDQ12.3 (4.1 to 23.1)
SecondaryFirst-line Treatment: Number of Participants With Shift of Response in OSDQ Score on Overall Health at the End of the First Stomatitis Episode

The OSDQ is a patient self-administered 6-item questionnaire with a 24-hour recall period. Participants completed the questionnaire daily up to the resolution of the stomatitis episode. The second item asked the participant to rate their overall health from 0 (worst possible) to 10 (perfect health). The overall health OSDQ scores are presented as the shift from Day 1 of first stomatitis episode value to the value at the end of the first episode of stomatitis. Day 1 is defined as the first OSDQ questionnaire recorded. End of first stomatitis value is defined as the last OSDQ questionnaire of the first episode of stomatitis. PROs were assessed up to 24 months after last patient's recruitment.

Time frame:
From start date of first stomatitis episode until its resolution, assessed up to 3.8 years
Reported as:
Count of participants · Participants
First-line Treatment: Number of Participants With Shift of Response in OSDQ Score on Overall Health at the End of the First Stomatitis Episode
ParticipantsEverolimus+Letrozole (First-line Treatment)
From 0 (Day 1) to 0 (end of first stomatitis)2
From 0 (Day 1) to 1 (end of first stomatitis)1
From 0 (Day 1) to 5 (end of first stomatitis)1
From 1 (Day 1) to 1 (end of first stomatitis)1
From 1 (Day 1) to 2 (end of first stomatitis)1
From 2 (Day 1) to 5 (end of first stomatitis)1
From 2 (Day 1) to 8 (end of first stomatitis)2
From 3 (Day 1) to 0 (end of first stomatitis)1
From 3 (Day 1) to 3 (end of first stomatitis)3
From 3 (Day 1) to 5 (end of first stomatitis)2
From 3 (Day 1) to 10 (end of first stomatitis)2
From 4 (Day 1) to 3 (end of first stomatitis)2
From 4 (Day 1) to 5 (end of first stomatitis)1
From 4 (Day 1) to 7 (end of first stomatitis)1
From 4 (Day 1) to 8 (end of first stomatitis)2
From 5 (Day 1) to 0 (end of first stomatitis)1
From 5 (Day 1) to 3 (end of first stomatitis)3
From 5 (Day 1) to 4 (end of first stomatitis)1
From 5 (Day 1) to 5 (end of first stomatitis)7
From 5 (Day 1) to 6 (end of first stomatitis)4
From 5 (Day 1) to 7 (end of first stomatitis)3
From 5 (Day 1) to 9 (end of first stomatitis)1
From 5 (Day 1) to 10 (end of first stomatitis)2
From 6 (Day 1) to 5 (end of first stomatitis)2
From 6 (Day 1) to 6 (end of first stomatitis)3
From 6 (Day 1) to 7 (end of first stomatitis)2
From 6 (Day 1) to 9 (end of first stomatitis)2
From 7 (Day 1) to 3 (end of first stomatitis)2
From 7 (Day 1) to 4 (end of first stomatitis)1
From 7 (Day 1) to 5 (end of first stomatitis)1
From 7 (Day 1) to 7 (end of first stomatitis)3
From 7 (Day 1) to 9 (end of first stomatitis)1
From 8 (Day 1) to 1 (end of first stomatitis)1
From 8 (Day 1) to 7 (end of first stomatitis)1
From 8 (Day 1) to 8 (end of first stomatitis)4
From 8 (Day 1) to 9 (end of first stomatitis)5
From 8 (Day 1) to 10 (end of first stomatitis)2
From 9 (Day 1) to 0 (end of first stomatitis)1
From 9 (Day 1) to 4 (end of first stomatitis)2
From 9 (Day 1) to 8 (end of first stomatitis)1
From 9 (Day 1) to 9 (end of first stomatitis)8
From 10 (Day 1) to 3 (end of first stomatitis)1
From 10 (Day 1) to 9 (end of first stomatitis)1
From missing value (Day 1) to missing value (end of first stomatitis)3
SecondaryFirst-line Treatment: Number of Participants With Shift of Response in OSDQ Score on Mouth and Throat Soreness at the End of the First Stomatitis Episode

The OSDQ is a patient self-administered 6-item questionnaire with a 24-hour recall period. Participants completed the questionnaire daily until the resolution of the stomatitis episode. The third item asked the participant to rate their mouth and throat soreness from 0 (no soreness) to 4 (extreme soreness). The mouth and throat soreness OSDQ scores are presented as the shift from Day 1 of first stomatitis episode value to the value at the end of the first episode of stomatitis. Day 1 is defined as the first OSDQ questionnaire recorded. End of first stomatitis value is defined as the last OSDQ questionnaire of the first episode of stomatitis. PROs were assessed up to 24 months after last patient's recruitment.

Time frame:
From start date of first stomatitis episode until its resolution, assessed up to 3.8 years
Reported as:
Count of participants · Participants
First-line Treatment: Number of Participants With Shift of Response in OSDQ Score on Mouth and Throat Soreness at the End of the First Stomatitis Episode
ParticipantsEverolimus+Letrozole (First-line Treatment)
From 0 (Day 1) to 0 (end of first stomatitis)3
From 1 (Day 1) to 0 (end of first stomatitis)22
From 1 (Day 1) to 1 (end of first stomatitis)12
From 1 (Day 1) to 2 (end of first stomatitis)3
From 2 (Day 1) to 0 (end of first stomatitis)13
From 2 (Day 1) to 1 (end of first stomatitis)7
From 2 (Day 1) to 2 (end of first stomatitis)4
From 2 (Day 1) to 3 (end of first stomatitis)1
From 3 (Day 1) to 0 (end of first stomatitis)9
From 3 (Day 1) to 1 (end of first stomatitis)4
From 3 (Day 1) to 2 (end of first stomatitis)5
From 3 (Day 1) to 3 (end of first stomatitis)1
From 3 (Day 1) to 4 (end of first stomatitis)1
From 4 (Day 1) to 1 (end of first stomatitis)2
From 4 (Day 1) to 2 (end of first stomatitis)1
From missing value (Day 1) to missing value (end of first stomatitis)4
SecondaryFirst-line Treatment: Number of Participants With Shift of Response in OSDQ Score on Mouth and Throat Soreness Limiting Swallowing, Drinking, Eating, Talking and Sleeping at the End of the First Stomatitis Episode

The OSDQ is a patient self-administered 6-item questionnaire with a 24-hour recall period. Participants completed the questionnaire daily until the resolution of the stomatitis episode. The fourth item asked the participant to rate how much their mouth and throat soreness limited them in 1) swallowing, 2) drinking, 3) eating, 4) talking and 5) sleeping. For each activity, mouth and throat soreness scores ranged from 0 (not limited) to 4 (unable to do). Scores are presented as the shift from Day 1 of first stomatitis episode value to the value at the end of the first episode of stomatitis. Day 1 is defined as the first OSDQ questionnaire recorded. End of first stomatitis value is defined as the last OSDQ questionnaire of the first episode of stomatitis. PROs were assessed up to 24 months after last patient's recruitment.

Time frame:
From start date of first stomatitis episode until its resolution, assessed up to 3.8 years
Reported as:
Count of participants · Participants
First-line Treatment: Number of Participants With Shift of Response in OSDQ Score on Mouth and Throat Soreness Limiting Swallowing, Drinking, Eating, Talking and Sleeping at the End of the First Stomatitis Episode
ParticipantsEverolimus+Letrozole (First Line Treatment)
Swallowing: From 0 (Day 1) to 0 (end of first stomatitis)40
Swallowing: From 0 (Day 1) to 1 (end of first stomatitis)3
Swallowing: From 0 (Day 1) to 2 (end of first stomatitis)1
Swallowing: From 1 (Day 1) to 0 (end of first stomatitis)7
Swallowing: From 1 (Day 1) to 1 (end of first stomatitis)6
Swallowing: From 1 (Day 1) to 2 (end of first stomatitis)3
Swallowing: From 1 (Day 1) to 3 (end of first stomatitis)1
Swallowing: From 2 (Day 1) to 0 (end of first stomatitis)6
Swallowing: From 2 (Day 1) to 1 (end of first stomatitis)4
Swallowing: From 2 (Day 1) to 2 (end of first stomatitis)2
Swallowing: From 3 (Day 1) to 0 (end of first stomatitis)8
Swallowing: From 3 (Day 1) to 1 (end of first stomatitis)2
Swallowing: From 3 (Day 1) to 3 (end of first stomatitis)2
Swallowing: From missing value (Day 1) to missing value (end of first stomatitis)7
Drinking: From 0 (Day 1) to 0 (end of first stomatitis)48
Drinking: From 0 (Day 1) to 1 (end of first stomatitis)4
Drinking: From 0 (Day 1) to 2 (end of first stomatitis)1
Drinking: From 1 (Day 1) to 0 (end of first stomatitis)10
Drinking: From 1 (Day 1) to 1 (end of first stomatitis)5
Drinking: From 1 (Day 1) to 2 (end of first stomatitis)1
Drinking: From 2 (Day 1) to 0 (end of first stomatitis)4
Drinking: From 2 (Day 1) to 1 (end of first stomatitis)3
Drinking: From 2 (Day 1) to 2 (end of first stomatitis)3
Drinking: From 2 (Day 1) to 3 (end of first stomatitis)2
Drinking: From 3 (Day 1) to 0 (end of first stomatitis)6
Drinking: From 3 (Day 1) to 1 (end of first stomatitis)1
Drinking: From 3 (Day 1) to 3 (end of first stomatitis)1
Drinking: From missing value (Day 1) to missing value (end of first stomatitis)9
Eating: From 0 (Day 1) to 0 (end of first stomatitis)17
Eating: From 0 (Day 1) to 1 (end of first stomatitis)2
Eating: From 0 (Day 1) to 2 (end of first stomatitis)1
Eating: From 1 (Day 1) to 0 (end of first stomatitis)14
Eating: From 1 (Day 1) to 1 (end of first stomatitis)11
Eating: From 1 (Day 1) to 2 (end of first stomatitis)2
Eating: From 2 (Day 1) to 0 (end of first stomatitis)8
Eating: From 2 (Day 1) to 1 (end of first stomatitis)3
Eating: From 2 (Day 1) to 2 (end of first stomatitis)4
Eating: From 2 (Day 1) to 3 (end of first stomatitis)2
Eating: From 3 (Day 1) to 0 (end of first stomatitis)7
Eating: From 3 (Day 1) to 1 (end of first stomatitis)6
Eating: From 3 (Day 1) to 2 (end of first stomatitis)3
Eating: From 3 (Day 1) to 3 (end of first stomatitis)4
Eating: From 4 (Day 1) to 1 (end of first stomatitis)1
Eating: From missing value (Day 1) to missing value (end of first stomatitis)7
Talking: From 0 (Day 1) to 0 (end of first stomatitis)45
Talking: From 0 (Day 1) to 1 (end of first stomatitis)5
Talking: From 1 (Day 1) to 0 (end of first stomatitis)12
Talking: From 1 (Day 1) to 1 (end of first stomatitis)2
Talking: From 2 (Day 1) to 0 (end of first stomatitis)5
Talking: From 2 (Day 1) to 1 (end of first stomatitis)2
Talking: From 2 (Day 1) to 2 (end of first stomatitis)3
Talking: From 2 (Day 1) to 3 (end of first stomatitis)1
Talking: From 3 (Day 1) to 0 (end of first stomatitis)4
Talking: From 3 (Day 1) to 2 (end of first stomatitis)1
Talking: From 3 (Day 1) to 3 (end of first stomatitis)3
Talking: From missing value (Day 1) to missing value (end of first stomatitis)9
Sleeping: From 0 (Day 1) to 0 (end of first stomatitis)48
Sleeping: From 0 (Day 1) to 1 (end of first stomatitis)4
Sleeping: From 0 (Day 1) to 2 (end of first stomatitis)1
Sleeping: From 1 (Day 1) to 0 (end of first stomatitis)8
Sleeping: From 1 (Day 1) to 1 (end of first stomatitis)2
Sleeping: From 1 (Day 1) to 2 (end of first stomatitis)2
Sleeping: From 2 (Day 1) to 0 (end of first stomatitis)4
Sleeping: From 2 (Day 1) to 1 (end of first stomatitis)3
Sleeping: From 2 (Day 1) to 2 (end of first stomatitis)6
Sleeping: From 3 (Day 1) to 0 (end of first stomatitis)1
Sleeping: From 3 (Day 1) to 1 (end of first stomatitis)1
Sleeping: From 3 (Day 1) to 2 (end of first stomatitis)1
Sleeping: From missing value (Day 1) to missing value (end of first stomatitis)11
SecondaryFirst-line Treatment: Number of Participants With Shift of Response in OSDQ Score on Mouth Pain Severity at the End of the First Stomatitis Episode

The OSDQ is a patient self-administered 6-item questionnaire with a 24-hour recall period. Participants completed the questionnaire daily until the resolution of the stomatitis episode. The fifth item asked the participant to rate their mouth pain severity from 0 (no pain) to 10 (unbearable pain). The mouth pain severity OSDQ scores are presented as the shift from Day 1 of first stomatitis episode value to the value at the end of the first episode of stomatitis. Day 1 is defined as the first OSDQ questionnaire recorded. End of first stomatitis value is defined as the last OSDQ questionnaire of the first episode of stomatitis. PROs were assessed up to 24 months after last patient's recruitment.

Time frame:
From start date of first stomatitis episode until its resolution, assessed up to 3.8 years
Reported as:
Count of participants · Participants
First-line Treatment: Number of Participants With Shift of Response in OSDQ Score on Mouth Pain Severity at the End of the First Stomatitis Episode
ParticipantsEverolimus+Letrozole (First-line Treatment)
From 0 (Day 1) to 0 (end of first stomatitis)5
From 1 (Day 1) to 0 (end of first stomatitis)10
From 1 (Day 1) to 1 (end of first stomatitis)6
From 1 (Day 1) to 2 (end of first stomatitis)1
From 1 (Day 1) to 3 (end of first stomatitis)1
From 1 (Day 1) to 5 (end of first stomatitis)1
From 2 (Day 1) to 0 (end of first stomatitis)6
From 2 (Day 1) to 3 (end of first stomatitis)1
From 3 (Day 1) to 0 (end of first stomatitis)7
From 3 (Day 1) to 1 (end of first stomatitis)1
From 3 (Day 1) to 2 (end of first stomatitis)2
From 3 (Day 1) to 3 (end of first stomatitis)1
From 3 (Day 1) to 4 (end of first stomatitis)2
From 4 (Day 1) to 0 (end of first stomatitis)4
From 4 (Day 1) to 1 (end of first stomatitis)2
From 4 (Day 1) to 4 (end of first stomatitis)1
From 4 (Day 1) to 5 (end of first stomatitis)1
From 5 (Day 1) to 0 (end of first stomatitis)3
From 5 (Day 1) to 1 (end of first stomatitis)1
From 5 (Day 1) to 2 (end of first stomatitis)1
From 5 (Day 1) to 3 (end of first stomatitis)1
From 5 (Day 1) to 4 (end of first stomatitis)1
From 5 (Day 1) to 5 (end of first stomatitis)1
From 5 (Day 1) to 6 (end of first stomatitis)1
From 5 (Day 1) to 7 (end of first stomatitis)1
From 5 (Day 1) to 10 (end of first stomatitis)1
From 6 (Day 1) to 0 (end of first stomatitis)2
From 6 (Day 1) to 1 (end of first stomatitis)1
From 6 (Day 1) to 2 (end of first stomatitis)1
From 6 (Day 1) to 5 (end of first stomatitis)1
From 6 (Day 1) to 6 (end of first stomatitis)1
From 6 (Day 1) to 8 (end of first stomatitis)1
From 7 (Day 1) to 0 (end of first stomatitis)2
From 7 (Day 1) to 1 (end of first stomatitis)2
From 7 (Day 1) to 2 (end of first stomatitis)1
From 7 (Day 1) to 7 (end of first stomatitis)1
From 8 (Day 1) to 0 (end of first stomatitis)3
From 8 (Day 1) to 2 (end of first stomatitis)1
From 8 (Day 1) to 4 (end of first stomatitis)2
From 8 (Day 1) to 5 (end of first stomatitis)1
From 8 (Day 1) to 6 (end of first stomatitis)1
From 8 (Day 1) to 9 (end of first stomatitis)1
From 9 (Day 1) to 0 (end of first stomatitis)2
From 9 (Day 1) to 9 (end of first stomatitis)1
From missing value (Day 1) to missing value (end of first stomatitis)4
SecondaryFirst-line Treatment: Number of Participants With Shift of Response in OSDQ Score on Mouth Pain Severity Affecting Daily Activities at the End of the First Stomatitis Episode

The OSDQ is a patient self-administered 6-item questionnaire with a 24-hour recall period. Participants completed the questionnaire daily until the resolution of the stomatitis episode. The sixth item asked the participant to rate their mouth pain severity affecting daily activities score from 0 (no effect on daily activities) to 10 (completely prevented from doing daily activities). The mouth pain severity affecting daily activities OSDQ scores are presented as the shift from Day 1 of first stomatitis episode value to the value at the end of the first episode of stomatitis. Day 1 is defined as the first OSDQ questionnaire recorded. End of first stomatitis value is defined as the last OSDQ questionnaire of the first episode of stomatitis. PROs were assessed up to 24 months after last patient's recruitment.

Time frame:
From start date of first stomatitis episode until its resolution, assessed up to 3.8 years
Reported as:
Count of participants · Participants
First-line Treatment: Number of Participants With Shift of Response in OSDQ Score on Mouth Pain Severity Affecting Daily Activities at the End of the First Stomatitis Episode
ParticipantsEverolimus+Letrozole (First-line Treatment)
From 0 (Day 1) to 0 (end of first stomatitis)33
From 0 (Day 1) to 1 (end of first stomatitis)1
From 0 (Day 1) to 5 (end of first stomatitis)1
From 1 (Day 1) to 0 (end of first stomatitis)7
From 1 (Day 1) to 1 (end of first stomatitis)4
From 1 (Day 1) to 4 (end of first stomatitis)2
From 2 (Day 1) to 0 (end of first stomatitis)6
From 2 (Day 1) to 1 (end of first stomatitis)1
From 2 (Day 1) to 2 (end of first stomatitis)3
From 2 (Day 1) to 3 (end of first stomatitis)1
From 2 (Day 1) to 4 (end of first stomatitis)1
From 3 (Day 1) to 0 (end of first stomatitis)3
From 3 (Day 1) to 1 (end of first stomatitis)3
From 3 (Day 1) to 2 (end of first stomatitis)1
From 3 (Day 1) to 3 (end of first stomatitis)1
From 3 (Day 1) to 4 (end of first stomatitis)1
From 4 (Day 1) to 0 (end of first stomatitis)2
From 5 (Day 1) to 0 (end of first stomatitis)2
From 5 (Day 1) to 1 (end of first stomatitis)1
From 5 (Day 1) to 2 (end of first stomatitis)1
From 5 (Day 1) to 3 (end of first stomatitis)1
From 5 (Day 1) to 5 (end of first stomatitis)1
From 5 (Day 1) to 6 (end of first stomatitis)1
From 6 (Day 1) to 1 (end of first stomatitis)1
From 6 (Day 1) to 5 (end of first stomatitis)1
From 6 (Day 1) to 8 (end of first stomatitis)1
From 7 (Day 1) to 0 (end of first stomatitis)1
From 8 (Day 1) to 0 (end of first stomatitis)1
From 8 (Day 1) to 8 (end of first stomatitis)1
From 8 (Day 1) to 10 (end of first stomatitis)1
From 9 (Day 1) to 0 (end of first stomatitis)1
From 9 (Day 1) to 8 (end of first stomatitis)1
From 10 (Day 1) to 10 (end of first stomatitis)1
From missing value (Day 1) to missing value (end of first stomatitis)4
SecondaryFirst-line Treatment (Stomatitis Sub-study): Time to First Stomatitis Episode as Assessed by the OSDQ

The time to first occurrence of stomatitis based on OSDQ is defined as time from first study treatment administration in the first line to start date of the first stomatitis episode recorded in the OSDQ. The OSDQ is a patient self-administered 6-item questionnaire with a 24-hour recall period. Participants completed the questionnaire daily until the resolution of the stomatitis episode. The first item asked the participants when they experienced the first symptoms of stomatitis. Start date of the first occurrence of stomatitis is defined as the first date ever recorded for this item in the questionnaire. PROs were assessed up to 24 months after last patient's recruitment. Only participants who were randomized in the stomatitis sub-study were included in this analysis.

Time frame:
From first study treatment administration in the first line until first stomatitis episode, assessed up to approximately 3.8 years
Reported as:
Median · Weeks
First-line Treatment (Stomatitis Sub-study): Time to First Stomatitis Episode as Assessed by the OSDQ
WeeksEverolimus+ Letrozole (First-line Treatment)
Dexamethasone1.4 (0.9 to 1.9)
Standard of care2.3 (0.7 to 5.4)
SecondaryFirst-line Treatment (Stomatitis Sub-study): Duration of First Stomatitis Based on OSDQ

The duration of the first stomatitis was calculated using the start and end date reported in the OSDQ. The OSDQ is a patient self-administered 6-item questionnaire with a 24-hour recall period. Participants completed the questionnaire daily until the resolution of the stomatitis. The first item asked the participants the date when they experienced the first symptoms of stomatitis. Start date of the first stomatitis is defined as the first date ever recorded for this item in the questionnaire. Stop date of the first stomatitis is defined as the last date the OSDQ was completed for this episode. Participants were censored if they died before resolution of stomatitis, received a new anticancer therapy, discontinued the study treatment with no resolution of the stomatitis or the stomatitis was still on-going at the cut-off. PROs were assessed up to 24 months after last patient's recruitment. Only participants who were randomized in the stomatitis sub-study were included in this analysis.

Time frame:
From start date of first stomatitis episode until its resolution, assessed up to 3.8 years
Reported as:
Median · Weeks
First-line Treatment (Stomatitis Sub-study): Duration of First Stomatitis Based on OSDQ
WeeksEverolimus+Letrozole (First-line Treatment)
DexamethasoneNA (NA to NA)
Standard of Care13.7 (1.4 to 13.7)
SecondaryFirst-line Treatment (Stomatitis Sub-study): Number of Participants With Shift of Response in OSDQ Score on Overall Health at the End of the First Stomatitis Episode

The OSDQ is a patient self-administered 6-item questionnaire with a 24-hour recall period. Participants completed the questionnaire daily until the resolution of the stomatitis episode. The second item asked the participant to rate their overall health from 0 (worst possible) to 10 (perfect health). The overall health OSDQ score are presented as the shift from Day 1 of first stomatitis episode value to the value at the end of the first episode of stomatitis. Day 1 is defined as the first OSDQ questionnaire recorded. End of first stomatitis value is defined as the last OSDQ questionnaire of the first episode of stomatitis. PROs were assessed up to 24 months after last patient's recruitment. Only participants who were randomized in the stomatitis sub-study were included in this analysis.

Time frame:
From start date of first stomatitis episode until its resolution, assessed up to 3.8 years
Reported as:
Count of participants · Participants
First-line Treatment (Stomatitis Sub-study): Number of Participants With Shift of Response in OSDQ Score on Overall Health at the End of the First Stomatitis Episode
ParticipantsEverolimus+Letrozole (First-line Treatment)
Dexamethasone: From 2 (Day 1) to 5 (end of first stomatitis)1
Dexamethasone: From 4 (Day 1) to 3 (end of first stomatitis)1
Dexamethasone: From 5 (Day 1) to 5 (end of first stomatitis)1
Dexamethasone: From 5 (Day 1) to 6 (end of first stomatitis)1
Dexamethasone: From 5 (Day 1) to 7 (end of first stomatitis)1
Dexamethasone: From 6 (Day 1) to 5 (end of first stomatitis)1
Dexamethasone: From 6 (Day 1) to 7 (end of first stomatitis)1
Dexamethasone: From 7 (Day 1) to 3 (end of first stomatitis)1
Dexamethasone: From 8 (Day 1) to 8 (end of first stomatitis)1
Dexamethasone: From 8 (Day 1) to 9 (end of first stomatitis)1
Dexamethasone: From 9 (Day 1) to 9 (end of first stomatitis)1
SoC: From 0 (Day 1) to 5 (end of first stomatitis)1
SoC: From 4 (Day 1) to 3 (end of first stomatitis)1
SoC: From 4 (Day 1) to 8 (end of first stomatitis)1
SoC: From 5 (Day 1) to 5 (end of first stomatitis)1
SoC: From 6 (Day 1) to 7 (end of first stomatitis)1
SoC: From 7 (Day 1) to 3 (end of first stomatitis)1
SoC: From 8 (Day 1) to 9 (end of first stomatitis)1
SoC: From 8 (Day 1) to 10 (end of first stomatitis)1
SoC: From 9 (Day 1) to 4 (end of first stomatitis)1
SoC: From 9 (Day 1) to 9 (end of first stomatitis)2
SoC: From missing value (Day 1) to missing value (end of first stomatitis)2
SecondaryFirst-line Treatment (Stomatitis Sub-study): Number of Participants With Shift of Response in OSDQ Score on Mouth and Throat Soreness at the End of the First Stomatitis Episode

The OSDQ is a patient self-administered 6-item questionnaire with a 24-hour recall period. Participants completed the questionnaire daily until the resolution of the stomatitis episode. The third item asked the participant to rate their mouth and throat soreness from 0 (no soreness) to 4 (extreme soreness). The mouth and throat soreness OSDQ scores are presented as the shift from Day 1 of first stomatitis episode value to the value at the end of the first episode of stomatitis. Day 1 is defined as the first OSDQ questionnaire recorded. End of first stomatitis value is defined as the last OSDQ questionnaire of the first episode of stomatitis. PROs were assessed up to 24 months after last patient's recruitment. Only participants who were randomized in the stomatitis sub-study were included in this analysis.

Time frame:
From start date of stomatitis episode until its resolution, assessed up to 3.8 years
Reported as:
Count of participants · Participants
First-line Treatment (Stomatitis Sub-study): Number of Participants With Shift of Response in OSDQ Score on Mouth and Throat Soreness at the End of the First Stomatitis Episode
ParticipantsEverolimus+Letrozole (First-line Treatment)
Dexamethasone: From 0 (Day 1) to 0 (end of first stomatitis)1
Dexamethasone: From 1 (Day 1) to 0 (end of first stomatitis)3
Dexamethasone: From 1 (Day 1) to 1 (end of first stomatitis)2
Dexamethasone: From 2 (Day 1) to 0 (end of first stomatitis)1
Dexamethasone: From 2 (Day 1) to 1 (end of first stomatitis)3
Dexamethasone: From 3 (Day 1) to 1 (end of first stomatitis)1
SoC: From 1 (Day 1) to 0 (end of first stomatitis)1
SoC: From 1 (Day 1) to 1 (end of first stomatitis)1
SoC: From 2 (Day 1) to 1 (end of first stomatitis)1
SoC: From 3 (Day 1) to 0 (end of first stomatitis)2
SoC: From 3 (Day 1) to 1 (end of first stomatitis1
SoC: From 3 (Day 1) to 2 (end of first stomatitis3
SoC: From 4 (Day 1) to 1 (end of first stomatitis1
SoC: From 4 (Day 1) to 2 (end of first stomatitis1
SoC: From missing value (Day 1) to missing value (end of first stomatitis)2
SecondaryFirst-line Treatment (Stomatitis Sub-study): Number of Participants With Shift of Response in OSDQ Score on Mouth and Throat Soreness Limiting Swallowing, Drinking, Eating, Talking and Sleeping at the End of the First Stomatitis Episode

The OSDQ is a patient self-administered 6-item questionnaire with a 24-hour recall period. Participants completed the questionnaire daily until the resolution of the stomatitis episode. The fourth item asked the participant to rate how much their mouth and throat soreness limited them in 1) swallowing, 2) drinking, 3) eating, 4) talking and 5) sleeping. For each activity, mouth and throat soreness scores ranged from 0 (not limited) to 4 (unable to do). Scores are presented as the shift from Day 1 of first stomatitis stomatitis value to the value at the end of the first episode of stomatitis. Day 1 is defined as the first OSDQ questionnaire recorded. End of first episode value is defined as the last OSDQ questionnaire of the first episode of stomatitis. PROs were assessed up to 24 months after last patient's recruitment. Only participants who were randomized in the stomatitis sub-study were included in this analysis.

Time frame:
From start date of first stomatitis episode until its resolution, assessed up to 3.8 years
Reported as:
Count of participants · Participants
First-line Treatment (Stomatitis Sub-study): Number of Participants With Shift of Response in OSDQ Score on Mouth and Throat Soreness Limiting Swallowing, Drinking, Eating, Talking and Sleeping at the End of the First Stomatitis Episode
ParticipantsEverolimus+Letrozole (First-line Treatment)
Swallowing (dexamethasone): From 0 (Day 1) to 0 (end of first stomatitis)6
Swallowing (dexamethasone): From 1 (Day 1) to 0 (end of first stomatitis)2
Swallowing (dexamethasone): From 1 (Day 1) to 1 (end of first stomatitis)1
Swallowing (dexamethasone): From 2 (Day 1) to 0 (end of first stomatitis)1
Swallowing (dexamethasone): From 2 (Day 1) to 2 (end of first stomatitis)1
Swallowing (SoC): From 0 (Day 1) to 0 (end of first stomatitis)5
Swallowing (SoC): From 1 (Day 1) to 2 (end of first stomatitis)1
Swallowing (SoC): From 2 (Day 1) to 0 (end of first stomatitis)1
Swallowing (SoC): From 2 (Day 1) to 1 (end of first stomatitis)2
Swallowing (SoC): From 3 (Day 1) to 0 (end of first stomatitis)1
Swallowing (SoC): From 3 (Day 1) to 1 (end of first stomatitis)1
Swallowing (SoC): From missing value (Day 1) to missing value (end of first stomatitis)2
Drinking (dexamethasone): From 0 (Day 1) to 0 (end of first stomatitis)6
Drinking (dexamethasone): From 1 (Day 1) to 0 (end of first stomatitis)2
Drinking (dexamethasone): From 1 (Day 1) to 1 (end of first stomatitis)1
Drinking (dexamethasone): From 2 (Day 1) to 0 (end of first stomatitis)1
Drinking (dexamethasone): From 2 (Day 1) to 2 (end of first stomatitis)1
Drinking (SoC): From 0 (Day 1) to 0 (end of first stomatitis)3
Drinking (SoC): From 0 (Day 1) to 1 (end of first stomatitis)2
Drinking (SoC): From 2 (Day 1) to 0 (end of first stomatitis)3
Drinking (SoC): From 2 (Day 1) to 1 (end of first stomatitis)1
Drinking (SoC): From 3 (Day 1) to 0 (end of first stomatitis)1
Drinking (SoC): From 3 (Day 1) to 1 (end of first stomatitis)1
Drinking (SoC): From missing value (Day 1) to missing value (end of first stomatitis)2
Eating (dexamethasone): From 0 (Day 1) to 0 (end of first stomatitis)3
Eating (dexamethasone): From 1 (Day 1) to 0 (end of first stomatitis)1
Eating (dexamethasone): From 1 (Day 1) to 1 (end of first stomatitis)2
Eating (dexamethasone): From 2 (Day 1) to 0 (end of first stomatitis)1
Eating (dexamethasone): From 2 (Day 1) to 1 (end of first stomatitis)2
Eating (dexamethasone): From 2 (Day 1) to 2 (end of first stomatitis)1
Eating (dexamethasone): From 3 (Day 1) to 1 (end of first stomatitis)1
Eating (SoC): From 1 (Day 1) to 0 (end of first stomatitis)2
Eating (SoC): From 1 (Day 1) to 1 (end of first stomatitis)1
Eating (SoC): From 2 (Day 1) to 0 (end of first stomatitis)1
Eating (SoC): From 3 (Day 1) to 0 (end of first stomatitis)1
Eating (SoC): From 3 (Day 1) to 1 (end of first stomatitis)2
Eating (SoC): From 3 (Day 1) to 2 (end of first stomatitis)3
Eating (SoC): From 4 (Day 1) to 1 (end of first stomatitis)1
Eating (SoC): From missing value (Day 1) to missing value (end of first stomatitis)2
Talking (dexamethasone): From 0 (Day 1) to 0 (end of first stomatitis)6
Talking (dexamethasone): From 1 (Day 1) to 0 (end of first stomatitis)1
Talking (dexamethasone): From 2 (Day 1) to 0 (end of first stomatitis)2
Talking (dexamethasone): From 2 (Day 1) to 1 (end of first stomatitis)1
Talking (dexamethasone): From 2 (Day 1) to 2 (end of first stomatitis)1
Talking (SoC): From 0 (Day 1) to 0 (end of first stomatitis)5
Talking (SoC): From 0 (Day 1) to 1 (end of first stomatitis)1
Talking (SoC): From 1 (Day 1) to 0 (end of first stomatitis)1
Talking (SoC): From 2 (Day 1) to 0 (end of first stomatitis)1
Talking (SoC): From 2 (Day 1) to 1 (end of first stomatitis)1
Talking (SoC): From 3 (Day 1) to 0 (end of first stomatitis)1
Talking (SoC): From 3 (Day 1) to 2 (end of first stomatitis)1
Talking (SoC): From missing value (Day 1) to missing value (end of first stomatitis)2
Sleeping (dexamethasone): From 0 (Day 1) to 0 (end of first stomatitis)7
Sleeping (dexamethasone): From 1 (Day 1) to 0 (end of first stomatitis)1
Sleeping (dexamethasone): From 2 (Day 1) to 0 (end of stomatitis)1
Sleeping (dexamethasone): From 2 (Day 1) to 1 (end of first stomatitis)1
Sleeping (dexamethasone): From 2 (Day 1) to 2 (end of first stomatitis)1
Sleeping (SoC): From 0 (Day 1) to 0 (end of first stomatitis)5
Sleeping (SoC): From 0 (Day 1) to 2 (end of first stomatitis)1
Sleeping (SoC): From 1 (Day 1) to 1 (end of first stomatitis)1
Sleeping (SoC): From 2 (Day 1) to 0 (end of first stomatitis)2
Sleeping (SoC): From 3 (Day 1) to 0 (end of first stomatitis)1
Sleeping (SoC): From 3 (Day 1) to 1 (end of first stomatitis)1
Sleeping (SoC): From missing value (Day 1) to missing value (end of first stomatitis)2
SecondaryFirst-line Treatment (Stomatitis Sub-study): Number of Participants With Shift of Response in OSDQ Score on Mouth Pain Severity at the End of the First Stomatitis Episode

The OSDQ is a patient self-administered 6-item questionnaire with a 24-hour recall period. Participants completed the questionnaire daily until the resolution of the stomatitis episode. The fifth item asked the participant to rate their mouth pain severity from 0 (no pain) to 10 (unbearable pain). The mouth pain severity OSDQ scores are presented as the shift from Day 1 of first stomatitis episode value to the value at the end of the first episode of stomatitis. Day 1 is defined as the first OSDQ questionnaire recorded. End of first stomatitis value is defined as the last OSDQ questionnaire of the first episode of stomatitis. PROs were assessed up to 24 months after last patient's recruitment. Only participants who were randomized in the stomatitis sub-study were included in this analysis.

Time frame:
From start date of first stomatitis episode until its resolution, assessed up to 3.8 years
Reported as:
Count of participants · Participants
First-line Treatment (Stomatitis Sub-study): Number of Participants With Shift of Response in OSDQ Score on Mouth Pain Severity at the End of the First Stomatitis Episode
ParticipantsEverolimus+Letrozole (First-line Treatment)
Dexamethasone: From 0 (Day 1) to 0 (end of first stomatitis)1
Dexamethasone: From 1 (Day 1) to 2 (end of first stomatitis)1
Dexamethasone: From 2 (Day 1) to 0 (end of first stomatitis)2
Dexamethasone: From 3 (Day 1) to 0 (end of first stomatitis)2
Dexamethasone: From 3 (Day 1) to 1 (end of first stomatitis)1
Dexamethasone: From 3 (Day 1) to 2 (end of first stomatitis)1
Dexamethasone: From 5 (Day 1) to 2 (end of first stomatitis)1
Dexamethasone: From 5 (Day 1) to 3 (end of first stomatitis)1
Dexamethasone: From 7 (Day 1) to 1 (end of first stomatitis)1
SoC: From 1 (Day 1) to 0 (end of first stomatitis)1
SoC: From 1 (Day 1) to 1 (end of first stomatitis)1
SoC: From 4 (Day 1) to 1 (end of first stomatitis)2
SoC: From 5 (Day 1) to 5 (end of first stomatitis)1
SoC: From 7 (Day 1) to 0 (end of first stomatitis)1
SoC: From 8 (Day 1) to 2 (end of first stomatitis)1
SoC: From 8 (Day 1) to 4 (end of first stomatitis)2
SoC: From 8 (Day 1) to 6 (end of first stomatitis)1
SoC: From 9 (Day 1) to 0 (end of first stomatitis)1
SoC: From missing value (Day 1) to missing value (end of first stomatitis)2
SecondaryFirst-line Treatment (Stomatitis Sub-study): Number of Participants With Shift of Response in OSDQ Score on Mouth Pain Severity Affecting Daily Activities at the End of the First Stomatitis Episode

The OSDQ is a patient self-administered 6-item questionnaire with a 24-hour recall period. Participants completed the questionnaire daily until the resolution of the stomatitis episode. The sixth item asked the participant to rate their mouth pain severity affecting daily activities score from 0 (no effect on daily activities) to 10 (completely prevented from doing daily activities). The mouth pain severity affecting daily activities OSDQ scores are presented as the shift from Day 1 of first stomatitis episode value to the value at the end of the first episode of stomatitis. Day 1 is defined as the first OSDQ questionnaire recorded. End of first stomatitis value is defined as the last OSDQ questionnaire of the first episode of stomatitis. PROs were assessed up to 24 months after last patient's recruitment. Only participants who were randomized in the stomatitis sub-study were included in this analysis.

Time frame:
From start date of first stomatitis episode until its resolution, assessed up to 3.8 years
Reported as:
Count of participants · Participants
First-line Treatment (Stomatitis Sub-study): Number of Participants With Shift of Response in OSDQ Score on Mouth Pain Severity Affecting Daily Activities at the End of the First Stomatitis Episode
ParticipantsEverolimus+Letrozole (First-line Treatment)
Dexamethasone: From 0 (Day 1) to 0 (end of first stomatitis)5
Dexamethasone: From 1 (Day 1) to 0 (end of first stomatitis)1
Dexamethasone: From 2 (Day 1) to 0 (end of first stomatitis)2
Dexamethasone: From 3 (Day 1) to 2 (end of first stomatitis)1
Dexamethasone: From 5 (Day 1) to 3 (end of first stomatitis)1
Dexamethasone: From 6 (Day 1) to 1 (end of first stomatitis)1
SoC: From 0 (Day 1) to 0 (end of first stomatitis)4
SoC: From 1 (Day 1) to 4 (end of first stomatitis)1
SoC: From 2 (Day 1) to 2 (end of first stomatitis)1
SoC: From 3 (Day 1) to 0 (end of first stomatitis)1
SoC: From 3 (Day 1) to 1 (end of first stomatitis)1
SoC: From 5 (Day 1) to 2 (end of first stomatitis)1
SoC: From 5 (Day 1) to 5 (end of first stomatitis)1
SoC: From 9 (Day 1) to 0 (end of first stomatitis)1
SoC: From missing value (Day 1) to missing value (end of first stomatitis)2
SecondaryNumber of Participants With Clinical Benfit During Extension Phase

Number of participants with clinical benefit as judged by the investigator during the extension phase. The extension phase for up to 3 years for participants who were continuing to benefit from study treatment following the end of the core study phase (24 months after last patient's recruitment) was added in the amendment 5 (dated 14-Feb-2017). Results are presented by line of treatment

Time frame:
From the end of core phase (upon approval of amendment 5) up to approximately 3 years
Reported as:
Count of participants · Participants
Number of Participants With Clinical Benfit During Extension Phase
ParticipantsEverolimus+Letrozole (First-line Treatment)Everolimus+Exemestane (Second-line Treatment)
Extension Week 1346
Extension Week 12305
Extension Week 24284
Extension Week 36233
Extension Week 48203
Extension Week 60183
Extension Week 72163
Extension Week 84133
Extension Week 96123
Extension Week 108123
Extension Week 120112
Extension Week 132101
Extension Week 14481
Extension End of treatment111
Post-hocAll Collected Deaths

On-treatment deaths in first line were collected from first dose of first-line treatment until the date of last administration of the first-line study treatment plus 28 days for participants not entering second-line or the minimum between the date of last administration of the first-line study treatment plus 28 days and the date of first administration of second-line study treatment minus one day for participants entering second line, up to 7.3 years. On-treatment deaths in second line were collected from first dose of second-line treatment to 28 days after the last administration of second-line treatment, up to 5.4 years. Post-treatment survival follow-up deaths were collected from day 29 after last dose of study treatment to end of study, up to 7.3 years. All deaths refer to the sum of on-treatment deaths and post-treatment deaths.

Time frame:
On-treatment deaths in first line: Up to 7.3 years. On-treatment deaths in second line: Up to 5.4 years. Post-treatment and all deaths: Up to 7.3 years
Reported as:
Number · Participants
All Collected Deaths
ParticipantsEverolimus + Letrozole/Exemestane (First-line and Second-line Treatment)
On -treatment deaths in first line11
On-treatment deaths in second line2
Post-treatment survival follow-up deaths49
All deaths62

Adverse events

Collected over First-line on-treatment: from the first first-line dose to 28 days post first-line treatment (or 1 day before second-line dose, whichever was earlier, for participants receiving second-line), up to 7.3 years. Second-line on-treatment: from first second-line dose to 28 days post second-line treatment, up to 5.4 years. Post-treatment deaths: from day 29 after final dose to end of study, up to 7.3 years.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Everolimus+Letrozole (First-line on Treatment)11/202 (5.4%)72/202 (35.6%)202/202 (100%)
Everolimus+Exemestane (Second-line On-treatment)2/53 (3.8%)8/53 (15.1%)43/53 (81.1%)
Everolimus+Letrozole/Exemestane (Post-treatment Survival Follow-up)49/125 (39.2%)——
Most frequent serious events
Showing 10 of 115
Most frequent serious events
EventEverolimus+Letrozole (First-line on Treatment)Everolimus+Exemestane (Second-line On-treatment)Everolimus+Letrozole/Exemestane (Post-treatment Survival Follow-up)
PneumoniaInfections and infestations9/2021/53—
DyspnoeaRespiratory, thoracic and mediastinal disorders6/2021/53—
AnaemiaBlood and lymphatic system disorders5/2020/53—
NauseaGastrointestinal disorders5/2020/53—
Bone painMusculoskeletal and connective tissue disorders5/2020/53—
Atrial fibrillationCardiac disorders4/2020/53—
VomitingGastrointestinal disorders4/2020/53—
CellulitisInfections and infestations4/2020/53—
PneumonitisRespiratory, thoracic and mediastinal disorders4/2021/53—
Abdominal painGastrointestinal disorders1/2021/53—
Most frequent other events
Showing 10 of 69
Most frequent other events
EventEverolimus+Letrozole (First-line on Treatment)Everolimus+Exemestane (Second-line On-treatment)Everolimus+Letrozole/Exemestane (Post-treatment Survival Follow-up)
StomatitisGastrointestinal disorders139/20210/53—
Weight decreasedInvestigations91/20215/53—
DiarrhoeaGastrointestinal disorders81/2022/53—
NauseaGastrointestinal disorders73/2024/53—
HypertriglyceridaemiaMetabolism and nutrition disorders72/2025/53—
AnaemiaBlood and lymphatic system disorders71/20211/53—
FatigueGeneral disorders70/2025/53—
CoughRespiratory, thoracic and mediastinal disorders70/2027/53—
Decreased appetiteMetabolism and nutrition disorders64/2025/53—
Oedema peripheralGeneral disorders63/2026/53—

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Everolimus+Letrozole/Exemestane (First-line Treatment and Second-line Treatment)
Mean63.5 ± 8.75
Sex: Female, Male
Sex: Female, Male(Participants)Everolimus+Letrozole/Exemestane (First-line Treatment and Second-line Treatment)
Female202
Male0
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Everolimus+Letrozole/Exemestane (First-line Treatment and Second-line Treatment)
Caucasian146
Black7
Asian44
Pacific islander1
Other4
08

Study locations

52 sites
  • University of Alabama Comprehensive Cancer Center SC-2
    Birmingham, Alabama 35294, United States
  • Banner MD Anderson Cancer Center
    Gilbert, Arizona 85234, United States
  • Loma Linda University Loma Linda
    Loma Linda, California 92354, United States
  • Breastlink Medical Group Dept. of BreastlinkResearchGrp
    Long Beach, California 90806, United States
  • Oncology Specialists, SC Advocate Medical Group-Niles
    Park Ridge, Illinois 60068-0736, United States
  • St. Francis Health Comprehensive Cancer Center
    Topeka, Kansas 66606-169, United States
  • Norton Healthcare Inc SC
    Louisville, Kentucky 40202, United States
  • Baystate Medical Center SC-2
    Springfield, Massachusetts 01199, United States
  • Saint Barnabas Medical Center CancerCenter of Saint Barnabas
    Livingston, New Jersey 07039, United States
  • University of New Mexico Hospital SC
    Albuquerque, New Mexico 87106, United States
  • Broome Oncology SC
    Johnson City, New York 13790, United States
  • Columbia University Medical Center- New York Presbyterian Columbia
    New York, New York 10032, United States
  • Cone Health Cancer Center
    Greensboro, North Carolina 27403, United States
  • East Texas Hematology Clinic SC
    Lufkin, Texas 75904, United States
  • Utah Cancer Specialists Dept.of Utah Cancer Spec. (3)
    Salt Lake City, Utah 84106, United States
  • Novartis Investigative Site
    Santa Rosa, La Pampa 6300, Argentina
  • Novartis Investigative Site
    Rosario, Santa Fe S2000KZE, Argentina
  • Novartis Investigative Site
    Porto Alegre, RS 90035-003, Brazil
  • Novartis Investigative Site
    Sao Paulo, SP 01317-002, Brazil
  • Novartis Investigative Site
    Sao Paulo, SP 04014-002, Brazil
  • Novartis Investigative Site
    Besancon cedex, 25030, France
  • Novartis Investigative Site
    Bordeaux, 33076, France
  • Novartis Investigative Site
    Hyères, 83400, France
  • Novartis Investigative Site
    Le Chesnay, 78157, France
  • Novartis Investigative Site
    Lyon, 69373, France
  • Novartis Investigative Site
    Nancy, 54000, France
  • Novartis Investigative Site
    Nantes Cedex, 44277, France
  • Novartis Investigative Site
    Kecskemet, Bacs Kiskun 6000, Hungary
  • Novartis Investigative Site
    Gyula, 5700, Hungary
  • Novartis Investigative Site
    Szekszard, 7100, Hungary
  • Novartis Investigative Site
    Nagoya-city, Aichi 467-8602, Japan
  • Novartis Investigative Site
    Sapporo-city, Hokkaido 003-0804, Japan
  • Novartis Investigative Site
    Shiwa-gun, Iwate 028-3695, Japan
  • Novartis Investigative Site
    Kawasaki-city, Kanagawa 216-8511, Japan
  • Novartis Investigative Site
    Kumamoto City, Kumamoto 860-8556, Japan
  • Novartis Investigative Site
    Seoul, 01812, Korea, Republic of
  • Novartis Investigative Site
    Seoul, 06273, Korea, Republic of
  • Novartis Investigative Site
    Seoul, 06351, Korea, Republic of
  • Novartis Investigative Site
    Maastricht, AZ 5800, Netherlands
  • Novartis Investigative Site
    Lisboa, 1400-038, Portugal
  • Novartis Investigative Site
    Lisboa, 1649-035, Portugal
  • Novartis Investigative Site
    Porto, 4200-072, Portugal
  • Novartis Investigative Site
    Salamanca, Castilla Y Leon 37007, Spain
  • Novartis Investigative Site
    Valencia, Comunidad Valenciana 46010, Spain
  • Novartis Investigative Site
    La Coruna, Galicia 15006, Spain
  • Novartis Investigative Site
    Bangkok, 10330, Thailand
  • Novartis Investigative Site
    Bangkok, 10400, Thailand
  • Novartis Investigative Site
    Bangkok, 10700, Thailand
  • Novartis Investigative Site
    Antalya, 07059, Turkey
  • Novartis Investigative Site
    Istanbul, 34303, Turkey
  • Novartis Investigative Site
    Izmir, 35040, Turkey
  • Novartis Investigative Site
    Bath, BA1 3NG, United Kingdom
09

References and documents

Publications

  • Royce M, Bachelot T, Villanueva C, Ozguroglu M, Azevedo SJ, Cruz FM, Debled M, Hegg R, Toyama T, Falkson C, Jeong J, Srimuninnimit V, Gradishar WJ, Arce C, Ridolfi A, Lin C, Cardoso F. Everolimus Plus Endocrine Therapy for Postmenopausal Women With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: A Clinical Trial. JAMA Oncol. 2018 Jul 1;4(7):977-984. doi: 10.1001/jamaoncol.2018.0060. PubMed 29566104 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2013 to primary completion in Dec 2015, 33 months.

Results were first posted in Feb 2022, 6 years 1 month after primary completion.

Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's 33 months is close to that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2012
First posted
Oct 3, 2012
StartActual
Mar 7, 2013
Primary completionActual
Dec 17, 2015
CompletionActual
Jan 13, 2021
Results first posted
Feb 9, 2022
Last update
May 3, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 3, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01698918
Responsible party
Sponsor
First posted
Oct 3, 2012
Start date
Mar 7, 2013
Primary completion
Dec 17, 2015
Completion
Jan 13, 2021
Results posted
Feb 9, 2022
Last update
May 3, 2023

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Everolimus · Letrozole

Start the discussion